Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts

Yoshihide Asano1, Hironobu Ihn, Kenichi Yamane

  • 1Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.

Insights

Scleroderma fibroblasts show impaired Smad7 regulation of TGF-beta signaling, contributing to the disease

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Fibrosis Research

Background:

  • Transforming Growth Factor-beta1 (TGF-beta1) stimulates extracellular matrix (ECM) synthesis in mesenchymal cells.
  • Autocrine TGF-beta loops are implicated in the pathogenesis of scleroderma, a fibrotic disorder.

Purpose of the Study:

  • To investigate the role of Smad7 and Smurfs in the negative regulation of TGF-beta signaling within the context of scleroderma.
  • To elucidate the mechanisms maintaining the autocrine TGF-beta loop in scleroderma fibroblasts.

Main Methods:

  • Comparison of Smad7 and Smurf levels in scleroderma and normal fibroblasts (in vivo and in vitro).
  • Analysis of Smad7 complex formation with TGF-beta receptors.
  • Assessment of Smad7's inhibitory effect on collagen and reporter gene promoter activity.
  • Evaluation of TGF-beta receptor type I protein stability.

Main Results:

  • Scleroderma fibroblasts display elevated Smad7 levels and impaired Smad7-mediated inhibition of TGF-beta signaling.
  • TGF-beta receptor type I protein stability is increased in scleroderma fibroblasts.
  • Smurf1 and Smurf2 levels are comparable between normal and scleroderma fibroblasts, and do not influence TGF-beta receptor type I stability.

Conclusions:

  • Disturbed negative regulation of TGF-beta signaling, specifically impaired Smad7 function, likely contributes to the persistent autocrine TGF-beta loop in scleroderma.
  • This study provides novel insights into the molecular mechanisms underlying fibrosis in scleroderma.